This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Fulcrum Therapeutics (FULC) Might Surprise This Earnings Season
by Zacks Equity Research
Fulcrum Therapeutics (FULC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Axsome's (AXSM) Q3 Earnings In Line, Pipeline Progresses
by Zacks Equity Research
Axsome (AXSM) earnings meet estimates in the third quarter. The company stretches the timeline for the NDA filing for AXS-05 and AXS-07. Shares fall.
Editas' (EDIT) Earnings Rise Y/Y in Q3, EDIT-101 in Focus
by Zacks Equity Research
Editas' (EDIT) bottom line grows year over year in the third quarter while revenues beat estimates. Stock rises is after-hours trading.
Agios' (AGIO) Q3 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Agios' (AGIO) earnings and revenues fall shy of estimates in the third quarter. The company lifts the lower end of 2020 sales guidance for its leukemia drug Tibsovo. Stock inches up.
ACADIA (ACAD) Q3 Earnings Miss, Nuplazid Drives Revenues Y/Y
by Zacks Equity Research
ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid. Stock dips in after-hours trading.
What's in the Cards for CVS Health (CVS) in Q3 Earnings?
by Zacks Equity Research
CVS Health's (CVS) Q3 earnings might have been affected by issues like lower prescription and soft front store volume due to decline in provider visits.
National Vision (EYE) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
National Vision's (EYE) contact lens revenue growth is expected to have remained impressive in Q3 on lesser impact of store closures.
Blueprint Medicines (BPMC) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Blueprint Medicines' (BPMC) both bottom and the top line trump estimates in Q3. Ayvakit's sales rise sequentially.
Why Earnings Season Could Be Great for Fulcrum Therapeutics (FULC)
by Zacks Equity Research
Fulcrum Therapeutics (FULC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bionano (BNGO) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Bionano's (BNGO) sales numbers will be in focus when it reports Q2 results later in the week.
5 Biotech Stocks Set to Outpace Q2 Earnings Estimates
by Kinjel Shah
Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.
Fulcrum Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Fulcrum Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Is Fulcrum Therapeutics (FULC) Stock a Solid Choice Right Now?
by Zacks Equity Research
Fulcrum Therapeutics (FULC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Fulcrum Therapeutics, Inc. (FULC) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Fulcrum Therapeutics, Inc. (FULC).
Acceleron, Fulcrum Therapeutics Ink Deal for Pulmonary Disease
by Zacks Equity Research
Acceleron (XLRN) signs a collaboration/license pact with Fulcrum Therapeutics aimed at identifying small molecules designed to modulate specific pathways targeting a pulmonary disease indication.
Company News For Aug 20, 2019
by Zacks Equity Research
Companies in the news are: EL, PANW, WB and FULC